Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms

Expert Review of Hematology

Volumn 3, Issue 1, 2010, Pages 23-33

  Ramakrishnan, Aravind ^a   Sandmaier, Brenda M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Bcr abl; Graft versus leukemia; JAK 2; Myeloproliferative neoplasm; Reduced intensity conditioning; Stem cell transplant

Indexed keywords

ALEMTUZUMAB; AURORA KINASE INHIBITOR; BORTEZOMIB; BUSULFAN; CALCINEURIN INHIBITOR; CARMUSTINE; CD45 ANTIBODY I 123; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DASTINIB; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; HISTONE DEACETYLASE INHIBITOR; IMATINIB; JANUS KINASE 2; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NILOTINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; TREOSULFAN; UNCLASSIFIED DRUG; VORINOSTAT;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BCR ABL GENE; BONE MARROW DEPRESSION; CANCER RELAPSE; CANCER THERAPY; CELL PROLIFERATION; CHRONIC DISEASE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG EFFICACY; GENE; GENETIC TRANSCRIPTION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HUMAN; ISOTOPE LABELING; LEUKEMIA; LIVER TOXICITY; LYMPH NODE IRRADIATION; MORTALITY; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NONHUMAN; OVERALL SURVIVAL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; REDUCED INTENSITY CONDITIONING REGIMEN; RELAPSE FREE SURVIVAL; REVIEW; T LYMPHOCYTE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; WHOLE BODY RADIATION;

BONE MARROW NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYELOPROLIFERATIVE DISORDERS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 77953390081     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.09.73     Document Type: Review

References (116)

1. Hoffman R, Prchal JT, Samuelson S, Ciurea SO, Rondelli D. Philadelphia chromosomenegative myeloproliferative disorders: biology and treatment. Biol. Blood Marrow Transplant. 13(Suppl. 1), 64-72 (2007).
2. Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. In: Hematology 2007: American Society of Hematology Education Program Book. Gewirtz AM, Winter JN, Zuckerman K (Eds). American Society of Hematology, Washington, DC, USA 240-245 (2006).
3. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH (Ed.). WHO, Lyon, France (2008).
4. Appelbaum FR, Clift R, Radich J, Anasetti C, Buckner CD. Bone marrow transplantation for chronic myelogenous leukemia. Semin. Oncol. 22, 405-411 (1995).
5. Maziarz RT. Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors? Curr. Opin. Hematol. 15, 127-133 (2008).
6. Zhan H, Spivak JL. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era. Clin. Adv. Hematol. Oncol. 7, 334-342 (2009).
7. Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779-1790 (2005).
8. Levine RL, Wadleigh M, Cools J et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387-397 (2005).
9. Baxter EJ, Scott LM, Campbell PJ et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061 (2005).
10. James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144-1148 (2005). (Pubitemid 40663494)
11. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat. Rev. Cancer 7, 673-683 (2007).
12. Scott B, Deeg HJ. Hemopoietic cell transplantation as curative therapy of myelodysplastic syndromes and myeloproliferative disorders. Best Pract. Res. Clin. Haematol. J. 19, 519-522 (2006).
13. Pardanani A, Hood J, Lasho T et al. TG101209, a small molecule JAK2- selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 21, 1658-1668 (2007).
14. Goh KC, Ong WC, Hu C et al. SB1518: a potent and orally active JAK2 inhibitor for the treatment of myeloproliferative disorders. Blood 110, 165A-166A, 538 (2007).
15. Mesa RA, Verstovsek S, Kantarjian HM et al. INCB018424, a selective JAK1/2 inhibitor, significantly improves the compromised nutritional status and frank cachexia in patients with myelofibrosis (MF). Blood 112(11), 621-622 (2008).
16. Moliterno AR, Roboz GJ, Carroll M, Luger S, Hexner E, Bensen-Kennedy DM. An open-label study of CEP-701 in patients with JAK2 V617F-positive polycythemia vera and essential thrombocytosis. Blood 112(11), 44 (2008).
17. Paquette R, Sokol L, Shah NP et al. A Phase I study of XL019, a selective JAK2 inhibitor, in patients with polycythemia vera. Blood 112(11), 971 (2008).
18. Pardanani AD, Gotlib J, Jamieson C et al. A Phase I study of TG101348, an orally bioavailable JAK2-selective inhibitor, in patients with myelofibrosis. Blood 112(11), 43-44 (2008).
19. Verstovsek S, Kantarjian HM, Pardanani AD et al. The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and postpolycythemia/ essential thrombocythemia myleofibrosis (Post PV/ETMF). Blood 112(11), 1762 (2008).
20. Verstovsek S, Pardanani AD, Shah NP. et al. A Phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis and post-polycythemia vera/ essential thrombocythemia myelofibrosis. Blood 112(11), 206-207 (2008).
21. Scott BL, Sandmaier BM. Outcomes with myeloid malignancies. In: Hematology 2006: American Society of Hematology Education Program Book. Berliner N, Linker C, Schiffer CA (Eds). American Society of Hematology, Washington, DC, USA 381-389 (2006).
22. Baron F, Storb R. Current roles for allogeneic hematopoietic cell transplantation following nonmyeloablative or reduced-intensity conditioning. Clin. Adv. Hematol. Oncol. 3, 799-813 (2005). (Pubitemid 41782646)
23. Barrett AJ, Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 20, 1661-1672 (2006).
24. Finke J, Nagler A. Viewpoint: what is the role of allogeneic haematopoietic cell transplantation in the era of reducedintensity conditioning - is there still an upper age limit? A focus on myeloid neoplasia. Leukemia 21, 1357-1362 (2007).
25. Sandmaier BM, Mackinnon S, Childs RW. Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives. Biol. Blood Marrow Transplant. 13(Suppl. 1), 87-97 (2007).
26. Antin JH. Reduced-Intensity Stem Cell Transplantation: "...whereof a little more than a little is by much too much". King Henry IV, part 1, I, 2. In: Hematology 2007: American Society of Hematology Education Program Book. Gewirtz AM, Winter JN, Zuckerman K (Eds). American Society of Hematology, Washington, DC, USA 47-54 (2007).
27. Alousi A, de Lima M. Reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Clin. Adv. Hematol. Oncol. 5, 560-570 (2007).
28. Storb R. Reduced-intensity conditioning transplantation in myeloid malignancies. Curr. Opin. Oncol. 21(Suppl. 1), S3-S5 (2009).
29. Storb RF, Champlin R, Riddell SR, Murata M, Bryant S, Warren EH. Non-myeloablative transplants for malignant disease. In: Hematology 2001: American Society of Hematology Education Program Book. Schechter GP, Broudy VC, Williams ME (Eds). The American Society of Hematology, Washington, DC, USA 375-391 (2001).
30. Baron F, Storb R. The immune system as a foundation for immunologic therapy and hematologic malignancies: a historical perspective. Best Pract. Res. Clin. Haematol. J. 19, 637-653 (2006).
31. Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneicmarrow grafts. N. Engl. J. Med. 300, 1068-1073 (1979).
32. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED; the Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N. Engl. J. Med. 304, 1529-1533 (1981).
33. Weiden PL, Flournoy N, Sanders JE, Sullivan KM, Thomas ED. Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplant. Proc. 13, 248-251 (1981).
34. Martin PJ, Hansen JA, Buckner CD et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 66, 664-672 (1985).
35. Maraninchi D, Gluckman E, Blaise D et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 2, 175-178 (1987).
36. Kolb HJ, Mittermüller J, Clemm Ch et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76, 2462-2465 (1990).
37. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86, 2041-2050 (1995).
38. Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 76, 1867-1871 (1990).
39. Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 77, 1660-1665 (1991).
40. Baron F, Maris MB, Sandmaier BM et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning. J. Clin. Oncol. 23, 1993-2003 (2005). (Pubitemid 46211379)
41. Kahl C, Storer BE, Sandmaier BM et al. Relapse risk among patients with malignant diseases given allogeneic hematopoietic cell transplantation after non-myeloablative conditioning. Blood 110, 2744-2748 (2007).
42. Giralt S, Ballen K, Rizzo D et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research. Biol. Blood Marrow Transplant. 15, 367-369 (2009).
43. Storb R, Yu C, Wagner JL et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89, 3048-3054 (1997).
44. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graftversus- tumor effects. Blood 97, 3390-3400 (2001).
45. Giralt S, Logan B, Rizzo D et al. Reducedintensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the National Marrow Donor Program. Biol. Blood Marrow Transplant. 13, 844-852 (2007).
46. Radich JP. The biology of CML blast crisis. In: Hematology 2007: American Society of Hematology Education Program Book. Gewirtz AM, Winter JN, Zuckerman K (Eds). American Society of Hematology, Washington, DC, USA 384-391 (2007).
47. Cortes J, Rousselot P, Kim DW et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or intolerant chronic myeloid leukemia in blast crisis. Blood 109, 3207-3213 (2007).
48. Radich JP, Olavarria E, Apperley JF. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. Hematol. Oncol. Clin. North Am. J. 18, 685-702 (2004).
49. Or R, Shapira MY, Resnick I et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101, 441-445 (2003).
50. Crawley C, Lalancette M, Szydlo R et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 105, 4532-4539 (2005). (Pubitemid 40720805)
51. Weisser M, Schleuning M, Ledderose G et al. Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease. Bone Marrow Transplant. 34, 1083-1088 (2004).
52. Ruiz-Arguelles GJ, Gomez-Almaguer D, Morales-Toquero A et al. The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic Phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant. 36, 1043-1047 (2005).
53. Kerbauy FR, Storb R, Hegenbart U et al. Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia 19, 990-997 (2005).
54. Kebriaei P, Detry MA, Giralt S et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood 110, 3456-3462 (2007).
55. Lange T, Deininger M, Brand R et al. BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning. Leukemia 18, 1468-1475 (2004).
56. Uzunel M, Mattsson J, Brune M, Johansson JE, Aschan J, Ringden O. Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after non-myeloablative conditioning and allogeneic stem cell transplantation. Blood 101, 469-472 (2003).
57. Dupriez B, Morel P, Demory JL et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 88, 1013-1018 (1996).
58. Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system. Cancer 106, 623-630 (2006).
59. Cervantes F, Dupriez B, Pereira A et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113, 2895-2901 (2009).
60. Papageorgiou SG, Castleton A, Bloor A, Kottaridis PD. Allogeneic stem cell transplantation as treatment for myelofibrosis. Bone Marrow Transplant. 38, 721-727 (2006).
61. Kerbauy DMB, Gooley TA, Sale GE et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol. Blood Marrow Transplant. 13, 355-365 (2007).
62. Devine SM, Hoffman R, Verma A et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 99, 2255-2258 (2002).
63. Kröger N, Holler E, Kobbe G et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood DOI:10.1182/ blood-2009-2007-234880 (2009) (Epub ahead of print).
64. Rondelli D, Barosi G, Bacigalupo A et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 105, 4115-4119 (2005).
65. Merup M, Lazarevic V, Nahi H et al. Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br. J. Haematol. 135, 367-373 (2006).
66. Snyder DS, Palmer J, Stein AS et al. Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Biol. Blood Marrow Transplant. 12, 1161-1168 (2006).
67. Laport GG, Sandmaier BM, Storer BE et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol. Blood Marrow Transplant. 14, 246-255 (2008).
68. Kroger N, Thiele J, Zander A et al. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Exp. Hematol. 35, 1719-1722 (2007).
69. Barosi G, Ambrosetti A, Centra A et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Blood 91, 3630-3636 (1998).
70. Guardiola P, Anderson JE, Bandini G et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study. Blood 93, 2831-2838 (1999).
71. Ciurea SO, Sadegi B, Wilbur A et al. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. Br. J. Haematol. 141, 80-83 (2008).
72. Slattery JT, Clift RA, Buckner CD et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 89, 3055-3060 (1997).
73. Kashyap A, Wingard J, Cagnoni P et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol. Blood. Marrow. Transplant. 8, 493-500 (2002).
74. Bacher U, Klyuchnikov E, Wiedemann B, Kroeger N, Zander AR. Safety of conditioning agents for allogeneic haematopoietic transplantation. Expert Opin. Drug Saf. 8, 305-315 (2009).
75. Cutting R, Mirelman A, Vora A. Treosulphan as an alternative to busulphan for myeloablative conditioning in paediatric allogeneic transplantation. Br. J. Haematol. 143, 748-751 (2008).
76. Kroger N, Shimoni A, Zabelina T et al. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant. 37, 339-344 (2006).
77. Shimoni A, Hardan I, Shem-Tov N, Rand A, Yerushalmi R, Nagler A. Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes. Leuk. Lymphoma 48, 2352-2359 (2007).
78. McDonald GB, Slattery JT, Bouvier ME et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 101, 2043-2048 (2003).
79. Carella AM, Champlin R, Slavin S, McSweeney P, Storb R. Mini-allografts: ongoing trials in humans (editorial). Bone Marrow Transplant. 25, 345-350 (2000).
80. Carella AM, Giralt S, Slavin S. Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia. Haematologica 85, 304-313 (2000). (Pubitemid 30340149)
81. Champlin R, Khouri I, Kornblau S et al. Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. Hematol. Oncol. Clin. North Am. J. 13, 1041-1057 (1999).
82. Pagel JM, Gooley TA, Rajendran J et al. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood DOI:10.1182/blood-2009-2003-213298 (2009) (Epub ahead of print).
83. de Lima M, Champlin RE, Thall PF et al. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia 22, 258-264 (2008).
84. Green DJ, Pagel JM, Nemecek ER et al. Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates. Blood 114, 1226-1235 (2009).
85. Nakamae H, Wilbur DS, Hamlin DK et al. Biodistribution, myelosuppression, and toxicities in mice treated with an anti- CD45 antibody labeled with the a-emitting radionuclides bismuth-213 or astatine-211. Cancer Res. 69, 2408-2415 (2009).
86. Pagel JM. Radioimmunotherapeutic approaches for leukemia: the past, present and future. Cytotherapy 10, 13-20 (2008).
87. Walter RB, Boyle KM, Appelbaum FR, Bernstein ID, Pagel JM. Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts. Blood 111, 4813-4816 (2008).
88. Kantarjian HM, O'Brien S, Cortes JE et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 100, 1590-1595 (2002). (Pubitemid 34925133)
89. Olavarria E, Ottmann OG, Deininger M et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 17, 1707-1712 (2003).
90. Hess G, Bunjes D, Siegert W et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective Phase II open-label multicenter study. J. Clin. Oncol. 23, 7583-7593 (2005).
91. Carpenter PA, Snyder DS, Flowers MED et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 109, 2791-2793 (2007).
92. Olavarria E, Siddique S, Griffiths MJ et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 110, 4614-4617 (2007).
93. Magro L, Catteau B, Coiteux V, Bruno B, Jouet JP, Yakoub-Agha I. Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD. Bone Marrow Transplant. 42, 757-760 (2008).
94. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109, 500-502 (2007).
95. Shah NP, Olszynski P, Sokol L et al. A Phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis. Blood 112(11), 44 (2008).
96. Martino R, Caballero MD, Simón JA et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 100, 2243-2245 (2002).
97. Kroger N, Perez-Simon JA, Myint H et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol. Blood Marrow Transplant. 10, 698-708 (2004).
98. Blaise DP, Boiron JM, Faucher C et al. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer 104, 1931-1938 (2005). (Pubitemid 41513177)
99. Barrett AJ, Le Blanc K. Prophylaxis of acute GVHD: manipulate the graft or the environment? Baillieres Best Pract. Res. Clin. Haematol. 21, 165-176 (2008).
100. Ho VT. Graft manipulation: T cell depletion and tumor cell purging. In: Hematopoietic Stem Cell Transplantation. Soiffer RJ (Ed.). Human Press, NJ, USA 653-686 (2008).
101. Mohty M, Bay JO, Faucher C et al. Graft-versus-host disease following allogeneic transplantation from HLAidentical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 102, 470-476 (2003). (Pubitemid 36841962)
102. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion. Ann. Intern. Med. 108, 806-814 (1988).
103. Chakrabarti S, Mackinnon S, Chopra R et al. High incidence of cytomegalovirus infection after non-myeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 99, 4357-4363 (2002).
104. Kohrt HE, Turnbull BB, Heydari K et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood 114, 1099-1109 (2009).
105. Lan F, Zeng D, Higuchi M, Huie P, Higgins JP, Strober S. Predominance of NK1.1+TCR ab+ or DX5+TCR ab+ T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: "natural suppressor" cells. J. Immunol. 167, 2087-2096 (2001).
106. Armand P, Gannamaneni S, Kim HT et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J. Clin. Oncol. 26, 5767-5774 (2008).
107. Valmori D, Tosello V, Souleimanian NE et al. Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells. J. Immunol. 177, 944-949 (2006).
108. Sun K, Welniak LA, Panoskaltsis-Mortari A et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc. Natl Acad. Sci. 101, 8120-8125 (2004).
109. Reddy P, Maeda Y, Hotary K et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versushost disease and preserves graft-versusleukemia effect. Proc. Natl Acad. Sci. USA 101, 3921-3926 (2004).
110. Krijanovski OI, Hill GR, Cooke KR et al. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood 94, 825-831 (1999).
111. Blazar BR, Weisdorf DJ, DeFor T et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versushost disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 108, 3216-3222 (2006).
112. Koreth J, Stevenson KE, Kim HT et al. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood 114, 3956-3959 (2009).
113. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 8, 726-736 (2008).
114. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363, 1439-1441 (2004).
115. Sorror ML, Maris MB, Storb R et al. Hematopoietic cell transplantation (HCT)- specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106, 2912-2919 (2005).
116. Sorror ML, Sandmaier BM, Storer BE et al. Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J. Clin. Oncol. 25, 4246-4254 (2007).